[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518528":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":40,"centralContacts":45,"locations":54,"responsibleParty":76,"collaborators":78,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":22,"maxAge":22,"enrollmentInfo":91,"targetDuration":22,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":104,"overallStatus":57,"whyStopped":22,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,16,20],{"label":9,"type":6,"description":10,"interventionNames":11},"Patients","Patients who have had at least one pregnancy and have a venous ulcer, diabetic ulcer or sickle cell ulcer",[12,13,14,15],"Other: Saliva sampling","Other: Blood sampling","Other: Interviews","Other: Clinical examination",{"label":17,"type":6,"description":18,"interventionNames":19},"Patient \"Controls group \"","Post-partum women of the same age but without wounds.",[12,13,14,15],{"label":21,"type":6,"description":22,"interventionNames":23},"Children",null,[12],[25,29,33,37],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":22},"Saliva sampling","HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.",[21,17,9],{"type":6,"name":30,"description":31,"armGroupLabels":32,"otherNames":22},"Blood sampling","Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells,\n\nThe following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out.",[17,9],{"type":6,"name":34,"description":35,"armGroupLabels":36,"otherNames":22},"Interviews","V2 and\u002For V3",[17,9],{"type":6,"name":38,"description":35,"armGroupLabels":39,"otherNames":22},"Clinical examination",[17,9],[41],{"name":42,"affiliation":43,"role":44},"Sélim ARACTINGI, MD, PHD","Dermatology unit, Cochin Hospital - APHP","STUDY_DIRECTOR",[46,50],{"name":42,"role":47,"phone":48,"phoneExt":22,"email":49},"CONTACT","00 33 1 58 41 18 13","selim.aractingi@aphp.fr",{"name":51,"role":47,"phone":52,"phoneExt":22,"email":53},"Marie Benhammani-Godard","00 33 1 58 41 11 90","marie.godard@aphp.fr",[55],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Dermatology unit - Cochin Hospital - APHP","RECRUITING","Paris","Île-de-France Region","75014","France","FR",{"type":64,"coordinates":65},"Point",[66,67],2.3488,48.85341,{"lat":67,"lon":66},[70,73],{"name":71,"role":47,"phone":72,"phoneExt":22,"email":49},"Sélim ARACTINGI, MD, PhD","0033 1 58 41 18 13",{"name":74,"role":75,"phone":22,"phoneExt":22,"email":22},"Bénédicte OULES, MD","SUB_INVESTIGATOR",{"type":77,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR",[79],{"name":80,"class":6},"URC-CIC Paris Descartes Necker Cochin","100518528","fetal-cell-receptors-repertoire-100518528",false,"NCT06031714","Fetal Cell Receptors Repertoire","\"Study of CCR Receptor Overexpression in Fetal Microchimeric Cells: Proof of Concept Before a Potential Clinical Trial\"","MoreCCR","Inclusion Criteria:\n\nCommon criteria :\n\n* Adult women,\n* Post-partum: having been pregnant for any length of time,\n* Having signed a free and informed consent form,\n* Primiparous or multiparous,\n* Affiliated to a health insurance\n\nPatients :\n\n\\- Patients with a venous, diabetic or sickle cell ulcer, or mixed ulcer\n\nControl group patients :\n\n* Volunteers,\n* Age-matched,\n* Without skin ulcers.\n\nThere are no specific criteria for children.\n\nExclusion Criteria:\n\n* Minors (for patients)\n* Under court protection, curatorship, guardianship (for patients)\n* Immunocompromised patients for any reason whatsoever\n* Refusal of consent\n* Refusal of blood and\u002For saliva samples for themselves or a member of their family",true,"ALL",{"count":92,"type":93},160,"ESTIMATED","INTERVENTIONAL",[96],"NA","The purpose of this study is to describe the transcriptomic profile of foetal cells in post-partum and more specifically to determine which chemokine receptors are overexpressed in foetal cells in post-partum women with wounds To do so, the investigators will isolate foetal cells from the peripheral blood of healthy controls post partum women as well as from post partum women with skin ulcers and then perform RNA sequencing.",[99,100,101,102,103],"Venous Ulcer","Sickle Cell Ulcer","Diabetic Ulcer","Post-partum Women","Mixed Ulcer",[105,106,107],"Microchimerism","Foetal stem cells","Receptors","2025-09-05",{"date":110,"type":111},"2025-09-12","ACTUAL",{"date":113,"type":111},"2024-02-06",{"date":115,"type":93},"2027-02-01",{"name":5,"class":6},1]